N-(6-Methoxybenzo[d]thiazol-2-yl)-3-(4-methoxyphenyl)-4-oxo-3,4-dihydrophthalazine-1-carboxamidoacetamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(6-Methoxybenzo[d]thiazol-2-yl)-3-(4-methoxyphenyl)-4-oxo-3,4-dihydrophthalazine-1-carboxamidoacetamide
• 英文别名: N-[2-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-2-oxoethyl]-3-(4-methoxyphenyl)-4-oxophthalazine-1-carboxamide
• 化学式: C₂₆H₂₁N₅O₅S
• 分子量: 515.5
• InChiKey: WLWIHRXVYJONEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  151
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Anti-CD70 combination therapy
  申请人：University of Bern

  公开号：US10391168B1

  公开（公告）日：2019-08-27

  Provided are methods and compositions for the treatment of a BCR-ABL1 related disorder (e.g., chronic myelogenous leukemia) using a therapeutic combination of a WNT signaling pathway inhibitor and a BCR-ABL1 tyrosine kinase inhibitor.

  本文提供了使用WNT信号通路抑制剂和BCR-ABL1酪氨酸激酶抑制剂的治疗组合来治疗BCR-ABL1相关疾病（如慢性粒细胞白血病）的方法和组合物。
• WNT PROTEIN SIGNALLING INHIBITORS
  申请人：Lum Lawrence

  公开号：US20110136813A1

  公开（公告）日：2011-06-09

  The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
• US20140255426A1
  申请人：——

  公开号：US20140255426A1

  公开（公告）日：2014-09-11
• Improved Differentiation Method
  申请人：Koninklijke Nederlandse Akademie Van Wetenschappen

  公开号：US20210040454A1

  公开（公告）日：2021-02-11

  The invention relates to differentiation methods for progenitor cells, e.g. mammalian epithelial stem cells, differentiation media for use in said methods, organoids and cells obtainable by said methods and uses, including therapeutic uses, thereof.
• US8445491B2
  申请人：——

  公开号：US8445491B2

  公开（公告）日：2013-05-21